Knowledge Graph
Graph explorer
Search resolved entities, walk their edges, and read the sentence behind every one.
Entities25 of 207,987
- large language modeltechnology1,048 mentions
- robotic manipulationmarket834 mentions
- artificial intelligencetechnology739 mentions
- reinforcement learningtechnology492 mentions
- density-functional theorytechnology386 mentions
- Transformertechnology372 mentions
- vision-language-action modeltechnology355 mentions
- agentic AItechnology353 mentions
- Vision-Language Modeltechnology321 mentions
- U.S. Food and Drug Administrationorganization320 mentions
- Microsoftorganization291 mentions
- Googleorganization277 mentions
- NVIDIAorganization265 mentions
- Model Context Protocoltechnology232 mentions
- machine learningtechnology204 mentions
- MarketsandMarketsorganization199 mentions
- Claudeproduct192 mentions
- AI agenttechnology188 mentions
- ChatGPTproduct178 mentions
- Anthropicorganization177 mentions
- integrated sensing and communicationtechnology176 mentions
- Amazon Web Services, Inc.organization174 mentions
- OpenAIorganization172 mentions
- diffusion modeltechnology170 mentions
- IBMorganization163 mentions
Entity
Ocugen, Inc.
organization2 mentionslast seen Nov 10, 2026
Biotechnology company developing gene therapies for blindness diseases.
Relationships 6
- Ocugen, Inc.developsOCU40099% confidence2 sources
- Ocugen, Inc.employsShankar Musunuri99% confidence2 sources
- Ocugen, Inc.partners withCelairis Therapeutics Holdings Pty Ltd94% confidence1 source
- Ocugen, Inc.suppliesRoots Pharmaceutical Company WLL93% confidence1 source
- Ocugen, Inc.developsmodifier gene therapy92% confidence1 source
- Ocugen, Inc.depends onmodifier gene therapy85% confidence1 source
Relationship
Ocugen, Inc.employsShankar Musunuri
99% confidence2 supporting mentions
Either name opens that entity’s relationships.
Sources 2
- filingSEC EDGARNov 10, 2026Ocugen, Inc. 8-K: Item 1.01: Entry into a Material Definitive Agreement; Item 7.01: Regulation FD Disclosure; Item 9.01: Financial Statements and Exhibits
Dr. Shankar Musunuri, Chairman, Chief Executive Officer, and Co-Founder of Ocugen
- filingSEC EDGAROct 15, 2026Ocugen, Inc. 8-K: Item 1.01: Entry into a Material Definitive Agreement; Item 7.01: Regulation FD Disclosure; Item 8.01: Other Events; Item 9.01: Financial Statements and Exhibits
Dr. Shankar Musunuri, Chairman, Chief Executive Officer and Co-founder of Ocugen